Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
Muhammad A. Khattak, John M. Kirkwood(UPMC Hillman Cancer Center), Mizuho Fukunaga‐Kalabis(Merck & Co., Inc., Rahway, NJ, USA (United States)), Luis de la Cruz‐Merino, Zeynep Eroglu(Moffitt Cancer Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Dirk Schadendorf(National Center for Tumor Diseases), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Federica De Galitiis(Istituto Dermopatico dell'Immacolata), Merrick I. Ross(Johns Hopkins University), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ruixuan Jiang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alexander M.M. Eggermont(University Medical Center Utrecht), Francesco Spagnolo(Martin University), Jean‐Jacques Grob(Aix-Marseille Université), Jason J. Luke(University of Chicago), Georgina V. Long(The University of Sydney), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Matteo S. Carlino(The University of Sydney), Ke Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Caroline Robert(Institut Gustave Roussy), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Jacek Mackiewicz(Poznan University of Medical Sciences)
Cited by 22
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k